1
|
Sowa G: Caveolae, caveolins, cavins and
endothelial cell function: new insights. Front Physiol.
2:1202102.
|
2
|
Guan TH, Chen G, Gao B, Janssen MR,
Uttarwar L, Ingram AJ and Krepinsky JC: Caveolin-1 deficiency
protects against mesangial matrix expansion in a nouse model of
type 1 diabetic nephropathy. Diabetologia. 56:2068–2077. 2013.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Thompson TC, Tahir SA, Li L, Watanabe M,
Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, et
al: The role of caveolin-1 in prostate cancer: clinical
implications. Prostate Cancer Prostatic Dis. 13:6–11. 2010.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Freeman MR, Yang W and Di Vizio D:
Caveolin-1 and prostate cancer progression. Adv Exp Med Biol.
729:95–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Li L, Ren C, Yang G, Goltsov AA, Tabata K
and Thompson TC: Caveolin-1 promotes autoregulatory, Akt-mediated
induction of cancer-promoting growth factors in prostate cancer
cells. Mol Cancer Res. 7:1781–1791. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Tahir SA, Yang G, Goltsov AA, Watanabe M,
Tabata K, Addai J, Fattah el MA, Kadmon D and Thompson TC: Tumor
cell-secreted caveolin-1 has proangiogenic activities in prostate
cancer. Cancer Res. 68:731–739. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Tahir SA, Frolov A, Hayes TG, Mims MP,
Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC and Kadmon D:
Preoperative serum caveolin-1 as a prognostic marker for recurrence
in a radical prostatectomy cohort. Clin Cancer Res. 12:4872–4875.
2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gumulec J, Sochor J, Hlavna M,
Sztalmachova M, Krizkova S, Babula P, Hrabec R, Rovny A, Adam V,
Eckschlager T, et al: Caveolin-1 as a potential high-risk prostate
cancer biomarker. Oncol Rep. 27:831–841. 2012.PubMed/NCBI
|
9
|
Sugie S, Mukai S, Tsukino H, Toda Y,
Yamauchi T, Nishikata I, Kuroda Y, Morishita K and Kamoto T:
Increased plasma caveolin-1 levels are associated with progression
of prostate cancer among Japanese men. Anticancer Res.
33:1893–1897. 2013.PubMed/NCBI
|
10
|
TombranTink J, Chader CG and Johnson LV:
PEDF: A pigment epithelium-derived factor with potent neuronal
differentiative activity. Exp Eye Res. 53:411–414. 1991. View Article : Google Scholar : PubMed/NCBI
|
11
|
Dawson DW, Volpert OV, Gillis P, Crawford
SE, Xu H, Benedict W and Bouck NP: Pigment epithelium-derived
factor: a potent inhibitor of angiogenesis. Science. 285:245–248.
1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Duh EJ, Yang HS, Suzuma I, Miyagi M,
Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, et al:
Pigment epithelium-derived factor suppresses ischemia-induced
retinal neovascularization and VEGF-induced migration and growth.
Invest Ophthalmol Vis Sci. 43:821–829. 2002.PubMed/NCBI
|
13
|
Yamagishi S, Amano S, Inagaki Y, Okamoto
T, Takeuchi M and Inoue H: Pigment epithelium-derived factor
inhibits leptin-induced angiogenesis by suppressing vascular
endothelial growth factor gene expression through anti-oxidative
properties. Microvasc Res. 65:186–190. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yamagishi S, Nakamura K, Matsui T, Inagaki
Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I,
Motomiya Y, et al: Pigment epithelium-derived factor inhibits
advanced glycation end product-induced retinal vascular
hyperpermeability by blocking reactive oxygen species-mediated
vascular endothelial growth factor expression. J Biol Chem.
281:20213–20220. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Matsui T, Nishino Y, Maeda S and Yamagishi
S: PEDF-derived peptide inhibits corneal angiogenesis by
suppressing VEGF expression. Microvasc Res. 84:105–108. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Doll JA, Stellmach VM, Bouck NP, Bergh AR,
Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J and
Crawford SE: Pigment epithelium-derived factor regulates the
vasculature and mass of the prostate and pancreas. Nat Med.
9:774–780. 2003. View
Article : Google Scholar : PubMed/NCBI
|
17
|
Hirsch J, Johnson CL, Nelius T, Kennedy R,
Riese Wd and Filleur S: PEDF inhibits IL8 production in prostate
cancer cells through PEDF receptor/phospholipase A2 and regulation
of NFκB and PPARγ. Cytokine. 55:202–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mirochnik Y, Aurora A, SchulzeHoepfner FT,
Deabes A, Shifrin V, Beckmann R, Polsky C and Volpert OV: Short
pigment epithelial-derived factor-derived peptide inhibits
angiogenesis and tumor growth. Clin Cancer Res. 15:1655–1663. 2009.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Gong Q, Qiu S, Li S, Ma Y, Chen M, Yao Y,
Che D, Feng J, Cai W, Ma J, et al: Proapoptotic PEDF functional
peptides inhibit prostate tumor growth-A mechanistic study. Biochem
Pharmacol. 92:425–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Abe R, Shimizu T, Yamagishi S, Shibaki A,
Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M,
et al: Overexpression of pigment epithelium-derived factor
decreases angiogenesis and inhibits the growth of human malignant
melanoma cells in vivo. Am J Pathol. 164:1225–1232. 2004.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Takenaka K, Yamagishi S, Jinnouchi Y,
Nakamura K, Matsui T and Imaizumi T: Pigment epithelium-derived
factor (PEDF)-induced apoptosis and inhibition of vascular
endothelial growth factor (VEGF) expression in MG63 human
osteosarcoma cells. Life Sci. 77:3231–3241. 2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Seki R, Yamagishi S, Matsui T, Yoshida T,
Torimura T, Ueno T, Sata M and Okamura T: Pigment
epithelium-derived factor (PEDF) inhibits survival and
proliferation of VEGF-exposed multiple myeloma cells through its
anti-oxidative properties. Biochem Biophys Res Commun. 431:693–697.
2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hoshina D, Abe R, Yamagishi SI and Shimizu
H: The role of PEDF in tumor growth and metastasis. Curr Mol Med.
10:292–295. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yamagishi S and Matsui T: Pigment
epithelium-derived factor (PEDF) and cardiometabolic disorders.
Curr Pharm Des. 20:2377–2386. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Matsui T, Higashimoto Y, Taira J and
Yamagishi S: Pigment epithelium-derived factor (PEDF) binds to
caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1
in endothelial cells. Biochem Biophys Res Commun. 441:405–410.
2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Taira J and Higashimoto Y: Caveolin-1
interacts with protein phosphatase 5 and modulates its activity in
prostate cancer cells. Biochem Biophys Res Commun. 431:724–728.
2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yamagishi S, Inagaki Y, Amano S, Okamoto
T, Takeuchi M and Makita Z: Pigment epithelium-derived factor
protects cultured retinal pericytes from advanced glycation end
product-induced injury through its antioxidative properties.
Biochem Biophys Res Commun. 296:877–882. 2002. View Article : Google Scholar : PubMed/NCBI
|
28
|
Ojima A, Ishibashi Y, Matsui T, Maeda S,
Nishino Y, Takeuchi M, Fukami K and Yamagishi S: Glucagon-like
peptide-1 receptor agonist inhibits asymmetric dimethylarginine
generation in the kidney of streptozotocin-induced diabetic rats by
blocking advanced glycation end product-induced protein arginine
methyltranferase-1 expression. Am J Pathol. 182:132–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Higashimoto Y, Matsui T, Nishino Y, Taira
J, Inoue H, Takeuchi M and Yamagishi S: Blockade by
phosphorothioate aptamers of advanced glycation end
products-induced damage in cultured pericytes and endothelial
cells. Microvasc Res. 90:64–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yamagishi S, Adachi H, Abe A, Yashiro T,
Enomoto M, Furuki K, Hino A, Jinnouchi Y, Takenaka K, Matsui T, et
al: Elevated serum levels of pigment epithelium-derived factor in
the metabolic syndrome. J Clin Endocrinol Metab. 91:2447–2450.
2006. View Article : Google Scholar : PubMed/NCBI
|
32
|
Tahir SA, Yang G, Ebara S, Timme TL, Satoh
T, Li L, Goltsov A, Ittmann M, Morrisett JD and Thompson TC:
Secreted caveolin-1 stimulates cell survival/clonal growth and
contributes to metastasis in androgen-insensitive prostate cancer.
Cancer Res. 61:3882–3885. 2001.PubMed/NCBI
|
33
|
Matsui T, Higashimoto Y and Yamagishi S:
Laminin receptor mediates anti-inflammatory and anti-thrombogenic
effects of pigment epithelium-derived factor in myeloma cells.
Biochem Biophys Res Commun. 443:847–851. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Petersen SV, Valnickova Z and Enghild JJ:
Pigment epithelium-derived factor (PEDF) occurs at a
physiologically concentration in human blood: purification and
characterization. Biochemical J. 374:199–206. 2003. View Article : Google Scholar
|
35
|
Fujimura T, Yamagishi S, Ueda S, Fukami K,
Shibata R, Matsumoto Y, Kaida Y, Hayashida A, Koike K, Matsui T, et
al: Administration of pigment epithelium-derived factor (PEDF)
reduces proteinuria by suppressing decreased nephrin and increased
VEGF expression in the glomeruli of adriamycin-injected rats.
Nephrol Dial Transplant. 24:1397–1406. 2009. View Article : Google Scholar : PubMed/NCBI
|
36
|
Matsui T, Nishino Y, Ojima A, Maeda S,
Tahara N and Yamagishi S: Pigment epithelium-derived factor
improves metabolic derangements and ameliorates dysregulation of
adipocytokines in obese type 2 diabetic rats. Am J Pathol.
184:1094–1103. 2014. View Article : Google Scholar : PubMed/NCBI
|